Financial Performance Summary - In 2025, the company achieved operating revenue of 525.57 million RMB, representing a year-on-year increase of 23.09% [2] - The net profit attributable to the parent company was 114.02 million RMB, showing a significant year-on-year growth of 122.01% [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 116.59 million RMB, with a year-on-year increase of 102.99% [2] - Total assets at the end of the reporting period reached 1,955.93 million RMB, up 11.35% year-on-year [2] - The equity attributable to the parent company was 1,492.15 million RMB, reflecting a year-on-year growth of 7.11% [2] Business Operations and Key Factors - The company's core business segment, DEL, maintained steady growth, contributing to overall profit enhancement due to high gross margins [3] - The UK subsidiary further solidified the development of the FBDD/SBDD platform, with milestone revenues achieved from client projects [3] - The OBT segment showed significant revenue growth through the commercialization of small nucleic acid projects, aided by the efficient operation of an automated high-throughput chemical synthesis platform [3] - The company reported a significant increase in operating profit of 125.67 million RMB, a year-on-year growth of 99.58% [5] - The total profit reached 125.91 million RMB, marking a year-on-year increase of 100.62% [5] Non-Operating Gains and Losses - The company experienced a decrease in fair value losses on financial liabilities, which positively impacted overall financial performance [4]

Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 104 million to 127 million yuan, representing an increase of 52.64 million to 75.64 million yuan compared to the previous year, which is a year-on-year increase of 102.50% to 147.29% [1] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 106 million to 129 million yuan, an increase of 48.56 million to 71.56 million yuan year-on-year, translating to a growth of 84.55% to 124.59% [1] Previous Year Performance - In 2024, the company reported a total profit of 62.76 million yuan, with a net profit attributable to shareholders of the parent company at 51.36 million yuan, and a net profit after deducting non-recurring gains and losses at 57.44 million yuan [1] - The earnings per share for 2024 was 0.13 yuan [1] Main Reasons for Performance Change - The company has established long-term stable collaborations with global partners, leading to steady progress in commercial projects. The core business segment, DEL, has maintained steady growth and high gross margins, contributing to overall profit improvement. The UK subsidiary has further solidified the development of the FBDD/SBDD platform, with revenue growth from key business segments and milestone income from DEL and FBDD/SBDD projects [1] - The OBT segment has shown significant commercial transformation, with revenue growth driven by the expansion of traditional nucleotide monomer synthesis and the introduction of delivery molecule-related services. The automated high-throughput chemical synthesis platform has also operated efficiently, boosting revenue from ChemSer services [1]

Core Viewpoint - Chengdu XianDao Pharmaceutical Development Co., Ltd. expects significant growth in net profit for the year 2025, projecting an increase of 102.50% to 147.29% compared to the previous year [1] Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company between 104 million yuan and 127 million yuan for 2025, representing an increase of 52.64 million yuan to 75.64 million yuan from the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 106 million yuan and 129 million yuan, an increase of 48.56 million yuan to 71.56 million yuan, which corresponds to a growth of 84.55% to 124.59% year-on-year [1] Previous Year Performance - In 2024, the company reported a total profit of 62.76 million yuan, with a net profit attributable to shareholders of the parent company at 51.36 million yuan, and a net profit after deducting non-recurring gains and losses of 57.44 million yuan [2][1] Reasons for Performance Change - The company has established long-term stable collaborations with global partners, leading to steady growth in core business segments, particularly in DEL (Design, Synthesis, and Screening of Drug Libraries), which has maintained a high gross margin [3] - The UK subsidiary has further solidified the development of the FBDD/SBDD platform, contributing to revenue growth from key business segments and milestone income from client projects [3] - The OBT segment has shown significant commercial transformation, with revenue growth driven by the integration of delivery molecule services and the efficient operation of an automated high-throughput chemical synthesis platform [3] - The decrease in fair value losses from financial liabilities has also positively impacted the overall profit [4]

Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 104 million to 127 million yuan, representing a year-on-year increase of 102.50% to 147.29% [1] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 106 million to 129 million yuan, reflecting a year-on-year increase of 84.55% to 124.59% [1] Group 2 - The core business segment, DEL, which includes design, synthesis, and screening of DEL libraries, has maintained steady growth and high gross margins, contributing to overall profit improvement [2] - The UK subsidiary has further solidified the steady development of the FBDD/SBDD platform, with milestone revenues achieved from client projects in both DEL and FBDD/SBDD [2] - The OBT segment has shown significant revenue growth by expanding traditional nucleotide monomer synthesis and achieving commercial transformation of small nucleic acid projects [2] - The automated high-throughput chemical synthesis platform designed and built by the company has operated efficiently, driving revenue growth in ChemSer services [2]